Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02646319 | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | completed | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Jun 6, 2019 | clinicaltrials |
| NCT03923998 | Adjuvant ChemoRadiotherapy Prior to Surgery in Stage IVa Oral Cancers | completed | Early Phase 1 | 8 | Indrayani Hospital and Cancer InstituteOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03179956 |
| Impact of Ribociclib on Head and Neck Squamous Cell Cancer |
| terminated |
| Early Phase 1 |
| 1 |
| Fox Chase Cancer CenterOTHER |
| 1 |
| Feb 25, 2019 |
| clinicaltrials |
| NCT02608736 | Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid(GAMA) | completed | Early Phase 1 | 42 | Barretos Cancer HospitalOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT02593929 | Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer | withdrawn | Early Phase 1 | 0 | University of PittsburghOTHER | 0 | Jun 8, 2017 | clinicaltrials |
| NCT01417442 | BRAF V600E Mutations In Papillary Thyroid Carcinoma | unknown | Early Phase 1 | 150 | Bezmialem Vakif UniversityOTHER | 1 | Aug 16, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Jun 6, 2019source: clinicaltrials